Tianjin Chest Hospital
天津市胸科医院
Listed for 5 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Tianjin Chest Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Lung cancer肺癌39 papers led
- Coronary heart disease冠心病36 papers led2 open trials led
- Congenital heart disease先天性心脏病4 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化3 papers led
- Fabry disease法布雷病1 paper led
Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Pancreatic cancer, Breast cancer, Glioma, Hepatoblastoma, Retinoblastoma, Chordoma, Osteosarcoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Lung cancer
肺癌Led 39 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.2%.
- Open trials led
- 0
- recruiting or about to
7 hospitals in Tianjin for lung cancer251 hospitals in China for lung cancer
Open trials with this hospital 9
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingRC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
- Phase
- Phase 3
- Started
- 2026-04
- Posted
- Registry
- NCT07416474
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 66 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Urumqi, Wenzhou, Wuhan, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yantai, Yinchuan, Zhengzhou, Zhuhai
- RecruitingA Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07586202
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin
- RecruitingA Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT06962865
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Jinan, Kunming, Linyi, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Yantai, Zhengzhou
- RecruitingPhase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
- Phase
- Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT07154706
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Jinan, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingA Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07182682
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 47 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xuzhou, Zhengzhou
- RecruitingStudy to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07185997
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xinxiang, Zhengzhou
- RecruitingA Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2023-06
- Posted
- Registry
- NCT05913089
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Fuzhou, Shanghai, Taiyuan, Tianjin, Weifang
- Not yet recruitingA Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT05990127
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luoyang, Nanchang, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou
- Enrolling by invitationEfficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
- Phase
- Phase 3
- Started
- 2021-08
- Posted
- Registry
- NCT04762459
Age 18 years to 130 years (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Kunming, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led39
- Enhanced pulmonary nodule detection with U-Net, YOLOv8, and swin transformer.
- Identifying diagnostic markers and establishing prognostic model for lung cancer based on lung cancer-derived exosomal genes.
- A radiomics-based machine learning model and SHAP for predicting spread through air spaces and its prognostic implications in stage I lung adenocarcinoma: a multicenter cohort study.
- Spatial transcriptomic analysis across histological subtypes reveals molecular heterogeneity and prognostic markers in early-stage lung adenocarcinoma.
- Kaempferitrin Regulates the Proliferation, Metastasis, and Immune Escape of Nonsmall Cell Lung Cancer by Inhibiting the Akt/NF-κB Pathway.
- Guanylate-binding proteins score and a CBFA2T3-included risk model define immune microenvironment and chemosensitivity in lung adenocarcinoma.
- Integrative modeling of malignant epithelial programs in EGFR-mutant LUAD via single-cell transcriptomics and multi-algorithm machine learning.
- Single-cell transcriptomic profiling reveals the heterogeneity of epithelial cells in lung adenocarcinoma lymph node metastasis and develops a prognostic signature.
- Development of a machine learning-derived dendritic cell signature for prognostic stratification in lung adenocarcinoma.
- Falcarindiol Suppresses Malignant Progression and Induces Ferroptosis in Non-Small Cell Lung Cancer by Regulating JAK/STAT3 Axis.
- Integrative single-cell and machine learning approach to characterize immunogenic cell death and tumor microenvironment in LUAD.
- A Machine Learning-Derived Taurine Metabolism Signature Predicts Prognosis and Immune Landscape in Lung Adenocarcinoma via Integrative Single-Cell Analysis.
- Sennoside A represses the malignant phenotype and tumor immune microenvironment of non-small cell lung cancer cells by inhibiting the TRAF6/NF-κB pathway.
- A nicotinamide metabolism-related gene signature for predicting immunotherapy response and prognosis in lung adenocarcinoma patients.
- Druggable genome-wide Mendelian randomization integrating GWAS and eQTL/pQTL data identifies targets for lung squamous cell carcinoma.
- Single-Cell and Spatial Transcriptomics-Based Research Reveals Association Between M2a Macrophages and Tumor Spread through Air Spaces in Lung Adenocarcinoma.
- Preoperative assessment of tertiary lymphoid structures in stage I lung adenocarcinoma using CT radiomics: a multicenter retrospective cohort study.
- Macrophage heterogeneity and oncogenic mechanisms in lung adenocarcinoma: insights from scRNA-seq analysis and predictive modeling.
- Integrative single-cell analysis of LUAD: elucidating immune cell dynamics and prognostic modeling based on exhausted CD8+ T cells.
- Sinensetin inhibits the movement ability and tumor immune microenvironment of non-small cell lung cancer through the inactivation of AKT/β-catenin axis.
- CRTAC1 identified as a promising diagnosis and prognostic biomarker in lung adenocarcinoma.
- CircPIM3 regulates taxol resistance in non-small cell lung cancer via miR-338-3p/TNFAIP8 axis.
- A pretreatment prediction model of grade 3 tumors classed by the IASLC grading system in lung adenocarcinoma.
- Screening of potential microbial markers for lung cancer using metagenomic sequencing.
- Real-world surgical treatment patterns and clinical outcomes in patients with stages IA-IIIA non-small cell lung cancer: a retrospective multicentric observational study involving 11,958 patients.
- Mediastinal cavernous hemangioma with concurrent primary lung adenocarcinoma.
- SETD1A-mediated H3K4me3 methylation upregulates lncRNA HOXC-AS3 and the binding of HOXC-AS3 to EP300 and increases EP300 stability to suppress the ferroptosis of NSCLC cells.
- Impact of preoperative biopsy on tumor spread through air spaces in stage I non-small cell lung cancer: a propensity score-matched study.
- Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer.
- Pretreatment prediction of tumour spread through air spaces in clinical stage I non-small-cell lung cancer.
- ZNF143 Expression is Associated with COPD and Tumor Microenvironment in Non-Small Cell Lung Cancer.
- Identification of Recurrent Insertions and Deletions in Exon 18 and 19 of Human Epidermal Growth Factor Receptor 2 as Potential Drivers in Non-Small-Cell Lung Cancer and Other Cancer Types.
- Multi-line treatment with tyrosine kinase inhibitors enabled in 4-year survival for patient with stage IV lung adenocarcinoma: a case report.
- Investigation of differentially expressed gene profile for cisplatin-treated lung cancer patients.
- The risk and prognostic factors for brain metastases in esophageal cancer patients: an analysis of the SEER database.
- Perioperative outcomes of combined heart surgery and lung tumor resection: a systematic review and meta-analysis.
- MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5.
- Glutathione S‑transferase ω 1 promotes the proliferation, migration and invasion, and inhibits the apoptosis of non‑small cell lung cancer cells, via the JAK/STAT3 signaling pathway.
- Elevated expression of ASF1B correlates with poor prognosis in human lung adenocarcinoma.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status26
- Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPD
- A Study to Explore Clinical Characteristics and Prognoses of N2 Patients With Non-small Cell Lung Cancer
- RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
- A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
- Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
- A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
- Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
- A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
- A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
- Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
- Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)
- Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)
- A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
- Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.
- Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium
- A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)
- A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China
- A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer
- Is Video-assisted Thoracoscopic Lobectomy a Clinical Alternative for Surgically Resectable Pathologic N2 NSCLC Patients
- Real-World Study on Adjuvant Therapy Combined With Shenlingcao Oral Liquid in Patients for Stage II and IIIA Non-small Cell Lung Cancer After Radical Resection
- A Study to Explore Prognoses of the Patients With N2 Non-small Cell Lung Cancer
- A Study to Evaluate Effectiveness and Safety of Surgeries in Elderly NSCLC Patients
- A Study to Explore Prognoses of NSCLC Patients Complicated With Oligometastases
- A Study to Evaluate Clinical Characteristics of Lung Cancer in Patients With Surgeries and Adjuvant Therapies
- A Study to Evaluate Effectiveness of Sublobar Dissection in Patients With Non-small Cell Lung Cancer
Other diseases
Coronary heart disease
冠心病Led 36 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.7%.
9 hospitals in Tianjin for coronary heart disease231 hospitals in China for coronary heart disease
Open trials with this hospital 4
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingTTE Improves Clinical Management of Stable Chest Pain
- Phase
- Not given
- Started
- 2025-01
- Posted
- Registry
- NCT07063147
Age 18 years to Not stated (registered criteria)
Led by Tianjin Chest HospitalTianjin
- RecruitingCCTA Improves Clinical Management of Stable Chest Pain
- Phase
- Not given
- Started
- 2016-01
- Posted
- Registry
- NCT04691037
Age 18 years to Not stated (registered criteria)
Led by Tianjin Chest Hospital; 2 listed hospitals as study sitesBeijing, Tianjin
- RecruitingEfficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
- Phase
- Phase 4
- Started
- 2025-11
- Posted
- Registry
- NCT07110415
Age 40 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Dalian, Daqing, Guangzhou, Guiyang, Hangzhou, Harbin, Huzhou, Jinan, Lanzhou, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Xi'an, Yantai, Yinchuan, Zhangjiakou, Zhuhai
- Not yet recruitingOptimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
- Phase
- N/A
- Started
- 2021-09
- Posted
- Registry
- NCT04995159
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 67 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Harbin, Hefei, Huai'an, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shantou, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Yinchuan, Zhanjiang, Zhengzhou, Zhongshan, Zhuhai, Zibo
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led36
- Relationship between coronary artery calcification and plaque vulnerability, a qualitative and quantitative optical coherence tomography study.
- Electrocardiographic and clinical predictors for in-hospital mortality in patients with acute myocardial infarction caused by left main coronary artery occlusion.
- A sensing strategy based on novel pyrene-functionalized MOFs for sVCAM-1 detection and prognostic assessment in coronary heart disease.
- Interventional treatment of non-spontaneously healed spontaneous coronary artery dissection: a case report.
- The relative and combined ability of stress hyperglycemia ratio and N-terminal pro-B-type natriuretic peptide to predict all-cause mortality in diabetic patients with multivessel coronary artery disease.
- Triglyceride-glucose Index as a Valuable Marker to Predict Severity of Coronary Artery Disease: A Retrospective Cohort Study.
- The Effect of Angiotensin Receptor Blockers on In-Stent Restenosis After Stent Implantation: A Meta-Analysis.
- Differential Expression of mRNA in Peripheral Blood Mononuclear Cells May Predict Postoperative Atrial Fibrillation in Coronary Artery Bypass Surgery Patients.
- Association of the PCSK6 rs1531817(C/A) polymorphism with the prognosis and coronary stenosis in premature myocardial infarction patients: a prospective cohort study.
- Proprotein convertase subtilisin/kexin 9 inhibitor downregulates microRNA-130a-3p expression in hepatocytes to alleviates atherosclerosis progression.
- Monocyte to high-density lipoprotein cholesterol ratio predicts restenosis of drug-eluting stents in patients with unstable angina pectoris.
- Comparison of clinical effects of coronary artery bypass grafting between left anterior small thoracotomy approach and lower-end sternal splitting approach.
- Diagnostic Performance of Machine Learning-Derived Radiomics Signature of Pericoronary Adipose Tissue in Coronary Computed Tomography Angiography for Coronary Artery In-Stent Restenosis.
- Lipoprotein Subfractions as Markers for Predicting the Presence and Severity of Coronary Artery Disease in Patients Undergoing Coronary Angiography.
- Electrocardiographic changes in acute myocardial infarction with acute occlusion of all triple coronary arteries.
- Comparison of two diagnostic strategies for patients with stable chest pain suggestive of chronic coronary syndrome: rationale and design of the double-blind, pragmatic, randomized and controlled OPERATE Trial.
- Comparison of risk assessment strategies incorporating coronary artery calcium score with estimation of pretest probability to defer cardiovascular testing in patients with stable chest pain.
- Characterization of lncRNA-associated ceRNA network to uncover novel potential biomarkers in coronary artery disease.
- Kinesiophobia and self-management behaviour related to physical activity in Chinese patients with coronary heart disease: The mediating role of self-efficacy.
- A five-parameter score for predicting saphenous vein graft degenerative and/or occlusive disease in recurring ischemic symptoms after one year post coronary artery bypass grafting.
- The Preventive Effect of Alprostadil on the Contrast-Induced Nephropathy of Coronary Heart Disease Treated by Percutaneous Coronary Intervention in Moderate and High-Risk Population Stratified by Mehran Score.
- Perioperative coronary artery spasm after off-pump coronary artery bypass grafting in the non-manipulated coronary artery.
- Correlation of triglyceride-glucose index and dyslipidaemia with premature coronary heart diseases and multivessel disease: a cross-sectional study in Tianjin, China.
- Impact of persistent subclinical hypothyroidism on clinical outcomes in non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention.
- Coronary calcification improves the estimation for clinical likelihood of obstructive coronary artery disease and avoids unnecessary testing in patients with borderline pretest probability.
- Comparison of Different Investigation Strategies to Defer Cardiac Testing in Patients With Stable Chest Pain.
- Correlation between platelet-derived growth factor-B gene polymorphism and coronary heart disease.
- Validation and Comparison of PROMISE and CONFIRM Model to Predict High-Risk Coronary Artery Disease in Symptomatic and Diabetes Mellitus Patients.
- Comparison of NICE and ESC strategy for risk assessment in women with stable chest pain: a coronary computed tomography angiography study.
- Inflammatory Indicators and Hematological Indices in Contrast-Induced Nephropathy Among Patients Receiving Coronary Intervention: A Systematic Review and Meta-Analysis.
- Glycosylated hemoglobin levels and the risk for contrast-induced nephropathy in diabetic patients undergoing coronary arteriography/percutaneous coronary intervention.
- Standard vs. double dose of intravenous nicorandil in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing elective coronary procedures.
- Flow reserve fraction: the optimal choice in lesion assessing and interventional guiding for patient with unstable angina pectoris and intermediate lesion wrapped with myocardial bridge: a case report.
- Clinical outcomes after percutaneous coronary intervention for early versus late and very late stent thrombosis: a systematic review and meta-analysis.
- Pcsk9 is associated with severity of coronary artery lesions in male patients with premature myocardial infarction.
- Bivalirudin in patients undergoing percutaneous coronary intervention and independent predictors of postoperative adverse events in these patients: A real world retrospective study.
All its trials on ClinicalTrials.gov, any status15
- TTE Improves Clinical Management of Stable Chest Pain
- CCTA Improves Clinical Management of Stable Chest Pain
- Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
- Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
- Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus
- Compare the Effectiveness and Safety of Two Different Kinds of Cutting Balloon in Coronary Artery Disease
- The Sensitivity and Specificity of CardioSimFFRct Analysis Software on Coronary Artery Stenosis
- Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis
- Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)
- Quantitative Flow Ratio (QFR) Guided Coronary Artery Bypass Grafting for Patients Undergoing Primary Valve Surgery With Concomitant Coronary Artery Disease
- Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast Medium
- Clinical and Genetic Characteristics of Coronary Artery Disease in Chinese Young Adults
- Optimal Antiplatelet Therapy for Chinese Patients With Coronary Artery Disease
- A Trial to Evaluate Efficacy of Heart-protecting Musk Pill
- Acarbose Cardiovascular Evaluation Trial
Other diseases
Congenital heart disease
先天性心脏病Led 4 of the 2,604 English-language PubMed papers on congenital heart disease with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Tianjin for congenital heart disease207 hospitals in China for congenital heart disease
No open trial on congenital heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led4
- Acute stent placement for dynamic airway collapse after cardiac surgery in congenital heart disease with bronchial stenosis: A case report.
- Interventional treatment of non-spontaneously healed spontaneous coronary artery dissection: a case report.
- Doppler Echocardiography Combined with NTproBNP/BNP in the Diagnosis of Pulmonary Artery Hypertension Associated with Congenital Heart Disease.
- Catheter ablation of idiopathic left fascicular ventricular tachycardia: Implications of false tendons for mapping and ablation.
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 3 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
10 hospitals in Tianjin for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingStudy Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Phase
- Phase 3
- Started
- 2026-09
- Posted
- Registry
- NCT07687459
Age 40 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led3
- Metformin enhanced the effect of pirfenidone on pulmonary fibrosis in mice.
- Baricitinib Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice by Inhibiting TGF-β1 Signaling Pathway.
- Idiopathic pleuroparenchymal fibroelastosis presenting in recurrent pneumothorax and bilateral pleural effusion: A case report.
All its trials on ClinicalTrials.gov, any status1
Other diseases
Fabry disease
法布雷病Led 1 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 1.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
2 hospitals in Tianjin for Fabry disease80 hospitals in China for Fabry disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
- Phase
- Not given
- Started
- 2025-11
- Posted
- Registry
- NCT07187440
Age 7 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Nanjing, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led1
All its trials on ClinicalTrials.gov, any status1
Getting in touch
Name card to show staff or a driver
天津市胸科医院
Tianjin Chest Hospital
天津
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.